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Understanding the role of common polymorphisms in modulating the clinical phe-
notype when they co‐occur with a disease‐causing lesion is of critical importance in
medical genetics. We explored the impact of apparently neutral common poly-
morphisms, using the gene encoding the urea cycle enzyme, ornithine transcarba-
mylase (OTC), as a model system. Distinct combinations of genetic backgrounds
embracing two missense polymorphisms were created in cis with the pathogenic
p.Arg40His replacement. In vitro enzymatic assays revealed that the polymorphic
variants were able to modulate OTC activity both in the presence or absence of the
pathogenic lesion. First, we found that the combination of the minor alleles of
polymorphisms p.Lys46Arg and p.Gln270Arg significantly enhanced enzymatic ac-
tivity in the wild‐type protein. Second, enzymatic assays revealed that the minor
allele of the p.Gln270Arg polymorphism was capable of ameliorating OTC activity
when combined in cis with the pathogenic p.Arg40His replacement. Structural
analysis predicted that the minor allele of the p.Gln270Arg polymorphism would
serve to stabilize the OTC wild‐type protein, thereby corroborating the results of
the experimental assays. Our findings demonstrate the potential importance of cis‐
interactions between common polymorphic variants and pathogenic missense mu-
tations and illustrate how standing genetic variation can modulate protein function.
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1 | INTRODUCTION
The establishment of clear and unambiguous genotype‐phenotype
correlations can be a challenging task when an array of clinical
phenotypic outcomes are associated with different lesions in the
same gene or even with the same pathogenic replacement. Such
clinical/phenotypic diversity is a strong indication that other fac-
tors, whether genetic (e.g., genetic modifiers) or environmental
(e.g., diet), are playing a role in modulating the phenotype‐
genotype correlation (Domingo et al., 2019; Hartman & Tullman‐
Ercek, 2019; Nadeau, 2001). In this study, we sought to explore
the impact of common polymorphic variants as intragenic genetic
modifiers using ornithine transcarbamylase (OTC) (E.C. 2.1.3.3) as
a model system.
The concept of genetic modifiers was first proposed 80 years
ago by J.B.S. Haldane (Haldane, 1941). Genetic modifiers may be
defined as genes/variants (either coding or noncoding) that are
capable of modifying the clinical/phenotypic effect of a pathogenic
mutation in a given gene (Nadeau, 2001; Rahit & Tarailo‐
Graovac, 2020; Weatherall, 2001). When such variants are located
within regulatory regions, they may alter gene regulation and ex-
pression, whereas when present within coding regions, they may
affect protein structure, function, stability, turnover, and protein‐
protein interactions (Zhang et al., 2012). Thus, in principle, genetic
modifiers may serve both to ameliorate or aggravate the phenotypic
consequences of a given pathogenic mutation (Lehner, 2011). Pre-
vious studies have identified genetic modifiers within the regulatory
regions of key genes involved in cystic fibrosis, sickle cell disease,
retinitis pigmentosa, and OTC deficiency (Cruz et al., 2014; Darrah
et al., 2010; Hillian et al., 2008; Jang et al., 2018; Li et al., 2020;
Luksan et al., 2010; Steinberg & Sebastiani, 2012) among others.
Missense polymorphic variants have also been identified as genetic
modifiers (Chen et al., 2001; Cooper et al., 2013; Dakal et al., 2017;
Li et al., 2018; Silva et al., 2004; van Leeuwen et al., 2016), an ex-
ample of which is p.His558Arg in the SCN5A gene
(NM_000335.5:c.1673A>G [p.His558Arg]) which, in combination
with pathogenic SCN5A lesions, serves to modulate the severity of
the Brugada syndrome phenotype (Makielski et al., 2003; Matsumura
et al., 2017; Niu et al., 2006; Poelzing et al., 2006).
Understanding the contribution that apparently neutral polymorphic
variation can make in modulating the clinical phenotype represents a key
step towards the realization of personalized genomic medicine. To ex-
plore this issue, we focussed on the X‐linked OTC gene which encodes a
urea cycle enzyme conserved in all mammalian species. OTC is a
homotrimeric enzyme of the urea cycle that catalyses the formation of
citrulline and inorganic phosphate from carbamoyl phosphate and or-
nithine (Shi et al., 2000; Smith & Garg, 2017). Deficiency of the enzyme
generally leads to hyperammonemia, seizures, coma, and in some cases,
premature death (Yamaguchi et al., 2006). More than 400 disease‐
causing mutations have been identified in the OTC gene, most of them
missense replacements (Caldovic et al., 2015; Stenson et al., 2020). The
majority of these lesions are private or found in very few families
(Yamaguchi et al., 2006). One exception is the p.Arg40His replacement
(NM_000531.5:c.119G>A [p.Arg40His]) which has been reported in a
number of distinct families as a consequence of both recurrent and
identical‐by‐descent mutation (Hidaka et al., 2020; Koya et al., 2019;
Matsuda et al., 1996; Nishiyori et al., 1997; Zhou, Huang, Ma &
Zhu, 2020). OTC activity measured from the necropsied liver of five
deceased patients with a confirmed p.Arg40His mutation has been found
to be between 1.3% and 12% of the wild‐type OTC level (Matsuda
et al., 1996) whereas the mutant (p.Arg40His‐harboring) OTC enzyme
expressed in vitro in COS‐1 cells exhibited 10.2% (Matsuda et al., 1996)
to 28% (Nishiyori et al., 1997) of wild‐type activity. The p.Arg40His
mutation has been associated with both the early onset and the late‐
onset phenotype in both females and males (Hidaka et al., 2020; Koya
et al., 2019; Zhou et al., 2020). In a few cases, the sudden appearance of
metabolic distress in otherwise apparently healthy carriers of the p.Ar-
g40His mutation has been suggested to be associated with specific acute
dietary changes (Cavicchi et al., 2014; Hidaka et al., 2020; Koya
et al., 2019; Pinner et al., 2010).
In addition to the numerous individually rare pathogenic lesions,
OTC also harbors two common polymorphic variants: p.Lys46Arg
(NM_000531.5:c.137A>G [p.Lys46Arg]), and p.Gln270Arg (NM_00
0531.5:c.809A>C [p.Gln270Arg]) whose putative functional significance
in terms of their influence on clinical/phenotypic heterogeneity has until
now remained unaddressed. To investigate whether these two missense
polymorphisms might act as intragenic modifiers of the OTC gene in
concert with the p.Arg40His deleterious mutation, we recreated in vitro
all the possible genetic backgrounds in which specific allelic combinations
of the polymorphic and deleterious variants could co‐exist, and evaluated
the resulting OTC enzymatic activity in each case.
2 | MATERIALS AND METHODS
2.1 | OTC allelic and haplotypic population
frequencies
Population frequencies of OTC polymorphic variants p.Lys46Arg
(rs1800321) and p.Gln270Arg (rs1800328) were obtained from
the gnomAD browser V2.2.1 (Karczewski et al., 2020). Haplotype
analysis was conducted using data from the 1000 Genomes Project
(1KGP) Phase 3 available from the Ensembl Genome Browser re-
lease 101 which included the following populations: African (Afri-
can Caribbean in Barbados, African ancestry in the Southwest US,
Esan in Nigeria, Gambian in Western Division, Luhya in Webuye,
Mende in Sierra Leone, Yoruba in Ibadan); American (Colombian in
Medellin, Mexican ancestry in Los Angeles, Peruvian in Lima,
Puerto Rican in Puerto Rico); East Asian (Chinese Dai in Xish-
uangbabba, Han Chinese in Beijing, Southern Han Chinese, Japa-
nese in Tokyo, Kinh in Ho Chi Minh City); European (Utah residents
with Northern and Western European ancestry, Finnish in Finland,
British in England and Scotland, Iberian populations in Spain,
Tuscany in Italy) and South Asian (Bengali in Bangladesh, Gujarati
Indian in Houston, Indian Telugu in the UK, Punjabi in Lahore, Sri
Lankan Tamils in the UK).
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2.2 | Isolation of the human OTC gene
Human liver RNA was purchased from Ambion™ (Thermo Fisher
Scientific). One microgram liver RNA was used for complementary
DNA (cDNA) synthesis with iScript™ cDNA Synthesis kit (Bio‐Rad)
according to the manufacturer's recommendations. The human OTC
full coding sequence (1065 base pair) was isolated from the cDNA by
polymerase chain reaction (PCR) and cloned into the pHTP0 vector
(NZYtech). PCR was performed with HotStarTaq® Master Mix Kit
(Qiagen) using tailed primers (forward 5ʹ‐TCAGCAAGGGCTGAG
GACCAGGGGACTTTGATAAG‐3ʹ and reverse 5ʹ‐TCAGCGGAAG
CTGAGGTTTCCCCATAAACCAACTCA‐3ʹ) for cloning into the
pHTP0 vector. PCR conditions were as follows: initial denaturation
at 95°C for 15min; 35 cycles of denaturation at 94°C for 30 s; an-
nealing at 58°C for 30 s; elongation at 72°C for 1 min 30 s; with a
final single 20min elongation step. PCR products were analyzed on a
1% agarose gel. Bands of the expected size were excised, purified
with NYZtech Gelpure (NZYtech), and ligated to pHTP0. pHTP0
plasmids were transformed into NZY5α competent cells (NZYtech).
Ampicillin‐resistant clones were selected and grown overnight for
plasmid purification with NZYtech Miniprep Kit (NZYtech). Plasmid
sequences were confirmed by in‐house Sanger sequencing.
2.3 | Site‐directed mutagenesis and cloning into
the expression vector
pHTP0 plasmids containing the OTC gene were used for site‐directed
mutagenesis to generate the requisite genetic backgrounds
(Figure 1a). For each background, a specific set of primers was used
(Figure 1b) and site‐directed mutagenesis PCR was performed using
the NZYMutagenesis Kit (NZYtech) according to the manufacturer's
instructions. PCR products were treated with DpnI and transformed
into NZYStar competent cells (NZYtech). Positive colonies were se-
lected and grown overnight for plasmid purification and sequenced
as described above. To transfer OTC constructs from pHTP0 to the
expression vector, PCR was performed using primers containing
in‐built restriction sites EcoRI (forward: 5ʹ‐ CACCGGAATTCATGC
TGTTTAATCTGAGGATCCT‐3ʹ) and SalI (reverse 5ʹ‐ ACGCGTCGA
CTCAAAATTTAGGCTTCTGGAGCT‐3ʹ). PCR was performed with
10 ng input plasmid DNA, 10 µM each primer, and Phusion Flash
High Fidelity PCR Mix (Thermo Fisher Scientific). PCR conditions
were as follows: initial denaturation at 98°C for 10 s, 35 cycles of
denaturation at 98°C for 1 s, annealing at 63°C for 5 s and elongation
at 72°C for 1min with a single final elongation step at 72°C for 20 s.
PCR products of the expected size on 1% agarose gel bands were
F IGURE 1 Genetic backgrounds and primer sets. (a) Schematic representation of the OTC genetic backgrounds analyzed in this study.
Wild‐type backgrounds are termed WT1‐WT4, and the corresponding backgrounds containing the p.Arg40His mutation are termed M1‐M4
accordingly. Red indicates pathogenic amino acid replacement, blue indicates non‐pathogenic amino acid replacement. (b) Primer sets and
strategies used to obtain each background sequence. OTC, ornithine transcarbamylase
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excised and purified as described above. Next, purified PCR products
and pIRES2‐AcGFP1 Vector (TAKARA Bio), were treated with the
corresponding restriction enzymes and ligated using T4 DNA ligase
(Invitrogen, Thermo Fisher Scientific). All purified plasmid sequences
were confirmed by Sanger sequencing.
2.4 | Cell culture and expression of OTC protein
The expression of OTC protein was performed in HEK293T cells
which lack endogenous OTC expression. HEK293T cells were
maintained in Dulbecco's modified Eagle's medium high glucose,
pyruvate, and supplemented with 10% fetal bovine serumand 5%
Penicillin/Streptomycin. Cells were seeded at a density of 3 × 105
cells/well in 24‐well plates. After 24 h, cells were transfected using
1.5 µg selected OTC plasmid (pIRES‐AEGFP‐OTC) and Lipofectamine
2000 reagent (Invitrogen, Thermo Fisher Scientific) in Opti‐MEM
reduced serum medium (Gibco, Thermo Fisher Scientific) according
to the manufacturer's guidelines. 24 h after transfection, cells were
inspected in the fluorescent cell imager ZOE™ (Bio‐RAD) to calculate
transfection efficiency, by counting the number of cells expressing
enhanced green fluorescent protein in relation to the total number of
cells in the same field and no significant transfection efficiency dif-
ferences were observed between backgrounds. Immediately after,
cells were collected using passive lysis buffer 5X (Promega) supple-
mented with 10 µl protease inhibitor, and stored at −80°C. For each
genetic background, three independent replicate assays were
performed.
2.5 | OTC activity assays
OTC activity assays were performed by adjusting the protocols de-
scribed by Ceriotti, 1973; Pierson et al., 1977 and Suriano
et al., 2007. Two chromogenic solutions were prepared:
Solution 1: antipyrine (4 g/L) + iron(III)sulfate (50mg/L) in sul-
furic acid 10% vol/vol
Solution 2: Brij®35 (0.3% wt/wt) + 2,3‐butanedione monoxime
(5 g/L) in acetic acid 5% vol/vol
All reagents and kits used in these activity assays were pur-
chased from Sigma‐Aldrich. Variable transfection efficiencies were
standardized through total protein quantification of cell lysates
using the Protein Quantification Kit‐Rapid. For each cell lysate
sample, both basal and total citrulline levels were determined. All
measurements were performed in 75 mM triethanolamine buffer
pH 6.75 (the pH was adjusted with HCl), and incubations were
performed in the dark. Total citrulline was determined by mixing
25 μl cell lysates containing 50 μg total protein, with 25 μl L‐
ornithine hydrochloride 99% (7.5 mM) and 25 μl lithium carba-
moylphosphate dibasic hydrate (75 mM). Basal citrulline levels
were determined by mixing 25 μl cell lysates containing 50 μg total
protein, with 50 μl TAE buffer. Citrulline standards were de-
termined by mixing 25 μl citrulline solution (1 mM) with 50 μl TAE
buffer. Samples were incubated for 30 min at 37°C; the enzymatic
reaction was stopped by adding 1.5 ml Solution 1 and 1.5 ml So-
lution 2, and samples were further incubated for 20 min at 95°C.
Next, 300 μl each sample was transferred in duplicate to a 96‐well
plate and sample absorbance read at 460 nm in a BioTek Synergy™
Mx Microplate Reader. OTC activity in milliunits was calculated











Atot corresponds to the absorbance reading in samples where
total citrulline was determined. Abas denotes the absorbance reading
in samples where basal citrulline was determined. Astd refers to the
absorbance reading in citrulline standards.
2.6 | Statistical analysis
Statistical analyses were performed after checking data for normality
(Shapiro–Wilk test), homogeneity of variances (Levene's test), and
statistical outliers. The analysis of variance was performed by ap-
plying an analysis of variance test followed by multiple comparisons
using either Tukey's test or the Dunn–Šidák correction. Significant
differences were accepted for tests yielding p values <.05. The sta-
tistical software package used was GraphPad Prism 7.00 (San Diego).
2.7 | Structural analysis
Comparative homology models of human OTC were constructed
using the PDB 1C9Y human OTC crystal structure with 1.9 Å re-
solution (Shi et al., 2000) as a template. We created a total of eight
homology models representing all possible genetic backgrounds, one
for each missense variant haplotype identified in combination with
the p.Arg40His mutation. Homology models were built using the
SwissModel workspace (Waterhouse et al., 2018), and structural
quality assessment of the models was performed by means of global
model quality estimation and QMEAN scores (Benkert et al., 2010;
Bertoni et al., 2017; Studer et al., 2019). Model visualization and
structural analysis were performed using PyMOL™ molecular gra-
phics system V.2.4.1 (Schrodinger, 2015). Structural stability analysis
was run on the DUET server (Pires et al., 2014).
3 | RESULTS
3.1 | Haplotypic structure of p.Lys46Arg
(rs1800321) and p.Gln270Arg (rs1800328) variants
Two polymorphic missense variants are known to occur in the human
OTC gene (p.Lys46Arg and p.Gln270Arg) (Azevedo et al., 2002), for
which the minor alleles attain frequencies of 0.19250 and 0.02912
(gnomAD v2.1.1), respectively. To assess the haplotype structure
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defined by these two variants in human populations, we included
current data from the 1KGP (1000 Genomes Project Consortium
et al., 2015), which presents information for a large number of po-
pulations. Out of the four possible haplotypes (Table 1), the most
abundant was haplotype H1, defined by the Lys46‐Gln270 (wild‐type
1 [WT1]) combination, followed by H2 with the Arg46‐Gln270 (WT2)
combination, H4 with both the alternative minor alleles Arg46‐
Arg270 (WT4) and finally H3 with Lys46‐Arg270 (WT3).
3.2 | OTC activity assays
The amount of citrulline produced by cells transfected with plasmids
encoding the full‐length wild‐type OTC protein (Lys46 + Gln270;
WT1) was determined, as well as by cells transfected with plasmids
encoding proteins harboring the p.Lys46Arg (WT2), p.Gln270Arg
(WT3), and p.Lys46Arg + p.Gln270Arg (WT4) variants and negative
controls (Mock) (Figure 2a). We also quantified the amount of ci-
trulline produced in non‐transfected HEK293T cells, as a negative
control. Cells transfected with Mock plasmids and non‐transfected
cells were found to contain very low OTC activity, approximately
9.5 mU (3%) (Figure 2a,b), similar to what Suriano et al. observed in
CHO cells expressing the Mock vector (Suriano et al., 2007). These
control assays allowed us to demonstrate the virtual lack of en-
dogenous citrulline in HEK293T cells but also to confirm that the
pIRES‐AEGFP plasmid alone cannot drive citrulline production. The
concentration of citrulline in cell lysates transfected with the plasmid
encoding any of the wild‐type OTC configurations (WT1, WT2, WT3,
and WT4) was significantly (p < .0001) higher in comparison to the
negative controls, Mock and non‐transfected cells (Table S1).
The enzymatic activity of WT1 OTC (239±52.9 mU) was similar
to the wild‐type OTC enzymes harboring the polymorphic variants





p.Gln270Arg A>G All populations African American East Asian European South Asian Background
H1 A A 0.851 0.614 0.840 0.997 0.721 0.962 WT1
H2 G A 0.135 0.383 0.137 0.00131 0.225 0.0237 WT2
H3 A G 0.00334 ‐ 0.00573 ‐ 0.0104 0.00696 WT3
H4 G G 0.009 ‐ 0.0172 0.00131 0.0431 0.00557 WT4
F IGURE 2 OTC enzymatic activity assays. (a) From left to right, OTC activity in cell lysates transfected with plasmids encoding wild‐type
(WT) OTC, OTC harboring the p.Lys46Arg polymorphism, OTC carrying the p.Gln270Arg polymorphic variant, and OTC carrying both the
p.Lys46Arg and p.Gln270Arg polymorphic variants. (b) From left to right, OTC activity in cell lysates transfected with plasmids encoding OTC
harboring the p.Arg40His pathogenic mutation, OTC harboring the p.Arg40His mutation and the p.Lys46Arg polymorphic variant, OTC
harboring the p.Arg40His mutation and the p.Gln270Arg polymorphic variant, OTC carrying the p.Arg40His mutation and both the p.Lys46Arg
p.Gln270Arg polymorphisms. *p < .05, **p < .01, ***p < .0005. All tested conditions are significantly different from negative controls (a); see also
Tables S1, S2, and S3 for detailed values. Mock: citrulline values (due to residual OTC activity) for cells transfected with an empty plasmid, Cells:
citrulline values of non‐transfected cells. OTC, ornithine transcarbamylase
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WT2 p.Lys46Arg (271 ± 48mU) and WT3 p.Gln270Arg
(253 ± 25.4mU) singly. However, the OTC enzyme carrying the
minor alleles of both polymorphic variants, WT4 (p.Lys46Arg +
p.Gln270Arg), exhibited significantly higher activity (346 ± 15mU)
compared to the WT1 background (p = .002) and to the WT2 and
WT3 backgrounds each of which carried only a single polymorphic
variant (p < .005).
By contrast, significantly lower OTC activity was observed in
those samples transfected with plasmids encoding OTC harboring
the p.Arg40His mutation alone (M1) or combined with the poly-
morphic variants p.Lys46Arg and/or p.Gln270Arg (M2, M3, and M4)
(Figure 2b) as compared with their wild‐type counterparts. The OTC
protein carrying the p.Arg40His mutation yielded approximately
37±4.6 mU of OTC activity, corresponding to a reduction to about
15% of wild‐type activity, concordant with the results of previous
studies (Matsuda et al., 1996; Nishiyori et al., 1997). Comparison of
the enzymatic activities of wild‐type OTC protein (WT1) with those
of OTC proteins harboring the p.Arg40His mutation (M1, M2, M3,
and M4) showed a significant (p < .0001) reduction of enzymatic
activity in all the latter (Table S2). OTC enzymes harboring the
combinations p.Arg40His + p.Lys46Arg (M2), p.Arg40His +
p.Gln270Arg (M3), and p.Arg40His + p.Lys46Arg + p.Gln270Arg (M4)
exhibited lower OTC activity (26.8 ± 3.3, 51.6 ± 14, and
27.7 ± 8.9 mU, respectively) than the corresponding wild‐type en-
zymes. Although the OTC enzymes carrying the p.Arg40His mutation
without either of the two polymorphic minor alleles showed low
enzymatic activity, this activity was still significantly higher than the
negative controls (p < .05) (Table S3). Pairwise comparison between
the enzymatic activities of the OTC proteins harboring the p.Ar-
g40His mutation alone or in combination with the minor alleles of
the missense polymorphisms revealed that the M3 protein (p.Ar-
g40His + p.Gln270Arg) displayed significantly increased enzymatic
activity as compared to M1 (p.Arg40His), whereas M2 and M4 en-
zymes behaved similarly. These results suggest that the p.Gln270Arg
variant may act as a genetic modifier of the p.Arg40His mutation in
vitro.
3.3 | Structural analysis of OTC
To explore the molecular mechanisms underlying the observed dif-
ferences in enzymatic activity, we investigated the structural al-
terations in the OTC protein caused by the pathogenic mutation
p.Arg40His and by the polymorphic variants p.Lys46Arg and
p.Gln270Arg. We began by evaluating the three‐dimensional proxi-
mity and possible spatial interactions between the amino acid re-
sidue harboring the pathogenic mutation (amino acid residue 40) and
the polymorphic missense variants (at amino acid residues 46 and
270), using 3D homology models constructed so as to recreate the
eight possible protein backgrounds. Asall crystal structures of the
human OTC protein available in the PDB database possess an argi-
nine at position 270, we built the ancestral background (WT1) by
changing the arginine to glutamine. A total of eight homology models
were generated, corresponding to the same backgrounds that were
tested in the enzymatic assays: that is, WT1, WT2, WT3, WT4, M1,
M2, M3, and M4. Initial analysis showed that the three residues of
interest, Arg40, Lys46, and Gln270, do not participate in any of the
homotrimers' protein–protein interactions. We also measured the
spatial distance between the three residues and found that Arg40
and Lys46 are located within 9.8 Å of each other (Site 1) whereas
Gln270 is located on the opposite side of the monomer (Site 2) at
distances of 20 and 30 Å from Lys46 and Arg40, respectively
(Figure 3a).
Structural analysis of Site 1 on the WT1 background revealed a
network of hydrogen bonds that serve to link Arg40 and Lys46 to
neighboring amino acid residues, but no direct interaction between
Arg40 and Lys46 was observed (Figure 3b). In the WT2 model
(p.Lys46Arg), we noted that the network of hydrogen bonds is pre-
served in comparison to the WT1 model, but that a new interchain
bond is formed between Arg46 and Tyr167. The predicted con-
servation of the overall network of hydrogen bonds is in accord with
p.Lys46Arg being a common variant with no significant structural or
functional impact on the protein. By contrast, the pathogenic muta-
tion, p.Arg40His (M1), was predicted to lead to the removal of three
hydrogen bonds, two with Glu52 and one with Asn47 (Figure 3b).
When we then considered the M2 model, which combines the His40
substitution with the minor allele Arg46 (p.Arg40His + p.Lys46Arg),
we noted that the impact was additive in terms of the predicted
alterations to the hydrogen bond network observed in the M1
(p.Arg40His) and WT2 (p.Lys46Arg) models, namely the loss of three
hydrogen bonds in relation to p.Arg40His plus the gain of one in-
terchain hydrogen bond with p.Lys46Arg.
In Site 2 (Figure 4), there is a network of four hydrogen bonds
that links Gln270 to four neighboring residues (Arg277, Gln273,
Gln271, and Ser267). In the WT3 model incorporating p.Gln270Arg,
we still observe four hydrogen bonds, but these are connected to
only three of the four neighboring amino acid residues. As in the case
of the p.Lys46Arg variant, the conservation of the hydrogen bond
network suggests that no major structural perturbations would be
expected as a consequence of the replacement of Gln270 by Arg, as
indeed is in accordance with the polymorphic frequency of this
p.Gln270Arg variant in the general population.
Structural analysis of the WT4, M3, and M4 models (p.Ly-
s46Arg + p.Gln270Arg, p.Arg40His + p.Lys46Arg, and p.Arg40His +
p.Lys46Arg + Gln270Arg, respectively) did not reveal any change in
the network of predicted hydrogen bonds in comparison to the
models previously analyzed (WT1, WT2, WT3, M1, and M2), possibly
due to the considerable distance between Sites 1 and 2 in the OTC
molecule.
As the loss of protein stability consequent to amino acid re-
placement is one of the main underlying causes of the disease phe-
notype (Yue et al., 2005), we next determined the impact of the
variants under study on the overall structural stability of the OTC
protein, by evaluating the change in Gibbs free energy (ΔΔG). We
submitted the different homology models to the Duet server that
aggregates two complementary tools, mCSM and SDM, to yield a
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consensus prediction of the change in protein stability upon a single
amino acid replacement (Pires et al., 2014). By measuring and com-
paring the change of free energy, ΔΔG, between the folded and
unfolded states of homology models harboring the pathogenic
mutation and the polymorphic variants in relation to the native
model, WT1, we aimed to infer the impact of each missense re-
placement on the structural stability of the protein (Kellogg
et al., 2011; Magesh & George Priya Doss, 2014; Pires et al., 2014).
F IGURE 3 Structural analysis of OTC
homology models. (a) Location of the three
amino acid residues of interest (Arg40,
Lys46, and Gln270) within the OTC
monomer showing approximate distances
between the target residues. (b) Detailed
view of the hydrogen bond network
alterations in Site 1 on various genetic
backgrounds; each genetic background is
indicated on the left. OTC, ornithine
transcarbamylase
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This analysis predicted that the pathogenic mutation p.Arg40His was
destabilizing. The polymorphic variant p.Lys46Arg was also predicted
by mCSM and Duet to be destabilizing, but not to the same extent as
p.Arg40His, whereas SDM predicted the p.Lys46Arg variant not to
be destabilizing. By contrast, stability analysis by mCSM, Duet, and
SDM of the model harboring the p.Gln270Arg variant produced a
unanimous prediction that the Arg allele would be associated with an
increase in stability.
4 | DISCUSSION
The OTC protein is an evolutionarily conserved enzyme that plays a
key role in the urea cycle, as evidenced by the hyperammonemia
(which may be lethal) caused by impairment of OTC activity. Al-
though a considerable number of disease‐causing mutations have
been reported in the OTC gene, only two missense variants are
known to occur in human populations at polymorphic frequencies:
p.Lys46Arg (rs1800321) and p.Gln270Arg (rs1800328). These var-
iants have generally been considered to be standing variation with-
out any significant functional impact on the wild‐type protein. In this
study, we first posed the question as to whether these protein var-
iants could serve to modify OTC enzymatic activity in vitro. Second,
we sought to explore the possibility that this standing polymorphic
variation can modulate enzymatic activity in the specific context of
the p.Arg40His pathogenic mutation.
To assess the potential impact of the two polymorphic OTC
variants in cis with the p.Arg40His substitution, we combined data
from in vitro activity assays with structural information from
homology modeling for several different OTC proteins carrying dis-
tinct combinations of the polymorphic variants and the pathogenic
p.Arg40His mutation.
Although the structural analysis revealed that both polymorphic
variants alter the native network of hydrogen bonds observed in
OTC (WT1) as well as alter the overall structural stability of the
protein, enzymatic assays disclose that all wild‐type OTC enzymes
(WT1, WT2, WT3, and WT4), irrespective of the polymorphic alleles
present, displayed high level of enzymatic activity (Figure 2a), an
expected finding as all these isoforms are present in the general
population (Table 1). We however noted significantly enhanced en-
zymatic activity in association with the WT4 enzyme that combined
the minor alleles of both polymorphisms in cis, in comparison with
the other wild‐type enzymes, a strong indication that these two al-
leles in combination have the potential to function as a genetic
modifier of OTC activity in the wild type background.
With respect to the various alternative versions of OTC har-
boring the p.Arg40His deleterious replacement, in vitro assays
showed residual enzymatic activity corresponding to approximately
15% of WT1 activity (Figure 2b). This concurs with literature records
reporting similar levels of enzymatic activity in liver samples ob-
tained post mortem from patients carrying the p.Arg40His mutation
(Matsuda et al., 1996) and with previous studies that characterized
this mutation in vitro (Matsuda et al., 1996; Nishiyori et al., 1997).
Although significantly reduced by comparison with wild‐type, the
level of enzymatic activity associated with the various versions of
OTC harboring the p.Arg40His mutation may well be enough to
F IGURE 4 Structural analysis of Site 2
in OTC homology models. OTC, ornithine
transcarbamylase
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sustain quasi‐normal metabolic status as several OTC deficiency
patients have been reported in the literature as presenting symp-
toms at distinct ages (Cavicchi et al., 2014; Hidaka et al., 2020;
Koya et al., 2019; Matsuda et al., 1996; Pinner et al., 2010; Ploechl
et al., 2001; Tuchman et al., 1994; Yoshino et al., 1990; Zhou
et al., 2020).
The functional characterization of OTC protein carrying the
p.Arg40His replacement in cis to the p.Lys46Arg and/or p.Gln270Arg
polymorphic variants revealed that the combination of Arg46 with
the pathogenic mutation p.Arg40His alone (M2), or in combination
also with Arg270 (M4), exhibited reduced enzymatic activity, al-
though this decrease was not significantly different from the activity
observed in association with the M1 background. By contrast,
functional characterization of OTC protein carrying the p.Arg40His
in cis with the p.Gln270Arg polymorphic variant (M3) showed that
the Arg270 allele contributed to a 37.8% increase in terms of OTC
activity when compared with the major Gln270 allele (M1). This
would therefore appear to be an example of what has been termed
“antagonistic epistasis” (Lehner, 2011) by which a missense variant at
a physically distant residue contributes to protein stability (Table 2)
and partial rescue of enzymatic activity when in cis with a patholo-
gical missense mutation. Even though a significant change in protein
activity was evident in vitro, we should be wary of extrapolating in
relation to the clinical phenotype of individuals harboring the
p.Gln270Arg polymorphic variant in cis to the p.Arg40His mutation
because the in vivo context will inevitability exhibit much greater
complexity. Moreover, in the specific setting of OTC deficiency, the
incremental increase in enzymatic activity afforded by the
p.Gln270Arg variant may be insufficient to maintain normal meta-
bolic status, thereby preventing the development of clinical symp-
toms caused by insufficient enzymatic activity to maintain normal
metabolic status.
The interplay between rare disease‐causing mutations and common
polymorphic variants has been documented for only a very limited
number of genes/proteins involved in human genetic disease (Chan
et al., 2006; Cheng et al., 2011; Cooper et al., 2010; Gonzalez &
Ostermeier, 2019; Lage et al., 2014; Li et al., 2018; Matsumura
et al., 2017; Niu et al., 2006; Poelzing et al., 2006; Raef et al., 2008; Silva
et al., 2004; Zhang et al., 2008). For instance, in the SCN5A gene, the well‐
known p.His558Arg polymorphic variant (NM_000335.5:c.1673A>G
[p.His558Arg]) has been demonstrated to modulate the effect of several
pathogenic mutations in the cardiac channel SCN5A (Makielski
et al., 2003; Niu et al., 2006). Moreover, in the context of the POLG gene,
the p.Glu1143Gly (NM_002693.2:c.3428A>G [p.Glu1143Gly]) poly-
morphic variant was found to ameliorate the effect of the pathogenic
p.Trp748Ser (NM_002693.2:c.2243G>C [p.Trp748Ser]) mutation in the
DNA polymerase gamma of an individual with ataxia‐neuropathy (Chan
et al., 2006). Another interesting example is the case of the p.Val141Met
[NM_006763.3:c.421G>A (p.Val141Met)] pathogenic mutation in the
BTG2‐encoded protein which can be suppressed by either one of two
polymorphic variants in cis (NM_006763.2:c.376G>T [p.Ala126Ser] and
NM_006763.2:c.434G>A [pp.Arg145Gln]) (Jordan et al., 2015).
Here we show that a specific polymorphic OTC variant,
p.Gln270Arg, acts as a modifier of an OTC mutation in vitro, possibly
by buffering the destabilizing effect of the p.Arg40His mutation.
Previous work has shown that the reduction in OTC activity con-
sequent to the p.Arg40His substitution was due to degradation of
the preprotein in the cytosol during mitochondrial import (Augustin
et al., 2000; Mavinakere et al., 2001). It is thus likely that the ob-
served spectrum of phenotypic severity depends on OTC enzymatic
degradation before mitochondrial import, and so the presence of
p.Gln270Arg, which appears to contribute to the stabilization of the
protein, might delay its early degradation. As our experiments did
not include any investigation of the import and processing of OTC
expressed in cells, further reasons to explain the precise mechanism
by which amino acid position 270 may contribute to protein stabi-
lization cannot be advanced.
Although our results appear promising in terms of increasing our
understanding of the intragenic molecular interactions that play a
role in mediating protein stability, they cannot at this stage be used
to predict the clinical severity of individuals harboring the OTC
p.Arg40His variant. Indeed, we still do not know whether the sub‐
group of patients who also possess the p.Gln270Arg variant manifest
less severe clinical symptoms (or experience a later age of onset)
than individuals with different combinations of genetic variants.
Moreover, the effect of the p.Arg40His mutation on the stability of
the OTC protein may prevail over that of the allelic combination of
polymorphic amino acid residues in relation to the phenotypic out-
come. This represents an important future research question to be
addressed. It should, however, be appreciated that the critical impact
of nongenetic factors, such as diet may render any definitive con-
clusion difficult to achieve.
In summary, we show in this study that putatively neutral missense
polymorphisms in the OTC protein have the potential to play a sig-
nificant role as genetic modifiers of a specific pathological mutation. It is
likely that many other similar instances of genetic modifiers of inherited
human conditions will eventually be discovered. They will await detailed
in vivo and in vitro analyses that should ultimately illuminate our un-
derstanding of the interplay between rare pathogenic mutations and
common apparently neutral variants. Thus, Haldane's (1941) words are
as true today as they were 80 years ago: “a great deal more work will be
required before we can judge whether the presence of modifiers….is
common or rare in the human species.”
TABLE 2 Structural stability analysis of models harboring the
variants p.Arg40His, p.Lys46Arg, and p.Gln270Arg in comparison to
wild‐type (ΔΔG = 0)
p.Arg40His p.Lys46Arg p.Gln270Arg
mCSM −1.457 −0.678 0.044
DUET −1.551 −0.303 0.382
SDM −0.13 0.26 0.38
Note: Values correspond to changes in Gibbs free energy (ΔΔGKcal/mol).
Negative values of ΔΔG indicate a protein destabilizing replacement,
whereas positive values of ΔΔG indicate a stabilizing replacement.
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